Earlier diagnosis and wider reimbursement are expanding access, led by biosimilars, oral JAK and IL-17 therapies. Asia-Pacific, telehealth and AI imaging offer key opportunities.
Ankylosing Spondylitis Treatment Market Number Of Ankylosing Spondy
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) — The “Ankylosing Spondylitis Treatment – Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)” has been added to ResearchAndMarkets.com’s offering.
Ankylosing Spondylitis Treatment Market to Reach USD 10.93 Billion by 2031, Growing at a 7.32% CAGR
The global ankylosing spondylitis treatment market was valued at USD 7.15 billion in 2025 and is projected to increase from USD 7.67 billion in 2026 to USD 10.93 billion by 2031. The market is expected to register a compound annual growth rate (CAGR) of 7.32% during the 2026-2031 forecast period. Growth is being supported by earlier diagnosis, rising disease awareness, expanding access to biologics and biosimilars, and continued innovation across targeted therapies.
Earlier Diagnosis Expands the Treatable Patient Population
Improved diagnostic criteria for early axial spondyloarthritis are enabling clinicians to begin treatment before structural damage becomes irreversible. Advances in genetic research, including the identification of ethnicity-specific HLA-B27 subtypes in East Asian populations, are also strengthening risk assessment and targeted screening.
Rheumatology capacity is expanding in major emerging markets, particularly China and India, where national registries are identifying more patients. Higher diagnosis rates are expected to increase demand for first-line nonsteroidal anti-inflammatory drugs (NSAIDs), established biologic therapies, and newer targeted treatments. These developments should support sustained growth in new patient treatment starts through 2031.
Biosimilar Access and Reimbursement Support Market Growth
Broader reimbursement coverage for biologics and biosimilars is reshaping the ankylosing spondylitis treatment market. In the United States, pharmacy benefit managers are increasingly prioritizing lower-cost biosimilars and introducing incentives that encourage patients to switch from originator products. Several European markets have achieved biosimilar adoption rates exceeding 70%, helping reduce treatment costs and broaden patient access.
Latin American payers are also adopting tiered formularies that include multiple biosimilars for the same reference medicine. The resulting competition is lowering average prices while increasing treatment volumes. Savings generated through biosimilar adoption may also support access to newer IL-17 and JAK inhibitors, contributing to overall market expansion.
High Biologic Costs Remain a Key Market Restraint
Despite improving access, the high cost of originator biologics continues to place pressure on public and private healthcare budgets. Payers are responding with stricter prior authorization requirements, step-therapy policies, and preferred-product agreements. Biosimilar adoption remains uneven in markets without automatic substitution policies or established reimbursement pathways.
Affordability challenges are particularly significant in emerging economies, where limited public funding can delay biologic treatment. Wider subsidy programs, stronger insurance coverage, and more competitive biosimilar pricing will be important to unlocking unmet demand.
Additional factors influencing the market include improved adherence associated with oral JAK inhibitors, AI-enabled MRI scoring that may accelerate clinical trials, and safety concerns related to JAK inhibitors and long-term immunosuppression.
TNF Inhibitors Maintain Market Leadership
TNF inhibitors accounted for 53.68% of the ankylosing spondylitis treatment market in 2025, supported by extensive clinical experience and broad payer coverage. However, competition from approved adalimumab biosimilars and the growing use of infliximab biosimilars are moderating revenue growth within the category.
IL-17 inhibitors, including secukinumab and ixekizumab, continue to gain adoption among biologic-naive patients. Dual-target therapies such as bimekizumab may attract patients switching from existing treatments, while JAK inhibitors are establishing a role among individuals who have not achieved adequate results with biologics. Their oral administration and broad cytokine activity may further support uptake, subject to applicable safety guidance.
NSAIDs are forecast to record an 8.79% CAGR through 2031, the highest growth rate among the assessed drug classes. Long-term evidence suggesting that continuous celecoxib treatment may slow spinal damage progression has renewed interest in selective COX-2 inhibitors. Individualized exercise programs used alongside therapies such as etoricoxib may also improve functional outcomes. Experimental approaches, including anti-GM-CSF antibodies and nanomedicine formulations, demonstrate the continued strength of the ankylosing spondylitis treatment pipeline.
Asia Pacific Forecast to Record the Fastest Regional Growth
North America represented 40.78% of global market revenue in 2025, reflecting its leadership in advanced therapeutics, biosimilar adoption, and digital disease-management tools. Early regulatory approvals, performance-based payer agreements, and remote monitoring platforms continue to influence treatment utilization, although formulary differences can create access disparities.
Asia Pacific is projected to achieve the fastest regional CAGR of 9.03% through 2031. Growth is being driven by expanding insurance coverage, government-supported biosimilar programs, and a larger network of rheumatology clinics. China is expected to remain a major contributor, while established reimbursement systems in Japan and South Korea support access to advanced therapies. India is also experiencing wider availability of infliximab and adalimumab beyond major metropolitan areas.
Europe maintains a stable market position through progressive biosimilar policies, pooled purchasing, and extensive real-world evidence programs. Value-based pricing and competitive tenders are broadening access while placing pressure on manufacturer margins. Continued investment in rheumatology infrastructure across Central and Eastern Europe is expected to support more consistent treatment availability and long-term growth in the global ankylosing spondylitis treatment market.
Key Topics Covered:
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing global prevalence & earlier diagnosis
4.2.2 Expanding reimbursement coverage for biologics & biosimilars
4.2.3 Oral JAK-inhibitors improving patient adherence
4.2.4 AI-enabled MRI scoring speeding clinical trial timelines
4.2.5 Treat-to-target guidelines accelerating therapy switches
4.2.6 Emerging dual-IL-17/23 biologics with superior radiographic control
4.3 Market Restraints
4.3.1 High cost & price-inflation of originator biologics
4.3.2 Safety warnings for JAK inhibitors & long-term immunosuppression
4.3.3 Inter-changeability scepticism slowing biosimilar uptake
4.3.4 Cold-chain logistics gaps in emerging markets
4.4 Pipeline Analysis
4.5 Regulatory Landscape
4.6 Porter’s Five Forces Analysis
4.6.1 Threat of New Entrants
4.6.2 Bargaining Power of Buyers/Patients
4.6.3 Bargaining Power of Suppliers
4.6.4 Threat of Substitutes
4.6.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value)
5.1 By Drug Class
5.1.1 NSAIDs
5.1.2 TNF Inhibitors
5.1.3 IL-17 Inhibitors
5.1.4 JAK Inhibitors
5.1.5 Biosimilars
5.1.6 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Sub-cutaneous
5.2.3 Intravenous
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Online Pharmacies
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 South Korea
5.4.3.5 Australia
5.4.3.6 Rest of Asia Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 AbbVie Inc.
6.3.2 Novartis AG
6.3.3 UCB S.A.
6.3.4 Amgen Inc.
6.3.5 Pfizer Inc.
6.3.6 Eli Lilly and Company
6.3.7 Johnson & Johnson (Inc. Janssen)
6.3.8 Boehringer Ingelheim GmbH
6.3.9 Celltrion Healthcare
6.3.10 Merck & Co., Inc.
6.3.11 Gilead Sciences, Inc.
6.3.12 Sanofi S.A.
6.3.13 Samsung Bioepis
6.3.14 Sun Pharma Industries Ltd.
6.3.15 Takeda Pharmaceutical Co.
6.3.16 Reliance Life Sciences
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/nq15hs
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
- Ankylosing Spondylitis Treatment Market Number Of Ankylosing Spondy
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
